Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma

• PLoS One
• v.10(5); 2015
• PMC4420770

PLoS One. 2015; 10(5): e0125443.

Published online 2015 May 5. doi:  10.1371/journal.pone.0125443

PMCID: PMC4420770

Laura Fernández-Bertolín,1,2 Joaquim Mullol,1,2,3 Mireya Fuentes-Prado,1,2 Jordi Roca-Ferrer,1,2 Isam Alobid,1,2,3César Picado,1,2,4 and Laura Pujols1,2,*

Christine Beeton, Academic Editor

Author information ► Article notes ► Copyright and License information ►

Abstract

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the upper airways frequently associated with asthma. Bacterial infection is a feature of CRSwNP that can aggravate the disease and the response to glucocorticoid treatment.

Objective

We examined whether the bacterial product lipopolysaccharide (LPS) reduces glucocorticoid receptor (GR) function in control nasal mucosa (NM) fibroblasts and in nasal polyp (NP) fibroblasts from patients with CRSwNP and asthma.

Increase in the Level of Proinflammatory Cytokine HMGB1 in Nasal Fluids of Patients With Rhinitis and its Sequestration by Glycyrrhizin Induces Eosinophil Cell Death

 Table of Contents > Abstract Original Article  Open Access        Clin Exp Otorhinolaryngol. 2015 Jun;8(2):123-128. English. Leonardo Cavone,1 Caterina Cuppari,2 Sara Manti,2 Luisa Grasso,2 Teresa Arrigo,2 Luca Calamai,1 Carmelo Salpietro,2 and Alberto Chiarugi1 Go to: Abstract Objectives The nuclear protein high mobility group protein box 1 (HMGB1) is a proinflammatory mediator that belongs to the alarmin family of proinflammatory mediators, and it has recently emerged as a key player in different acute and chronic immune disorders. Several lines of evidence demonstrate that HMGB1 is actively released extracellularly from immune cells or passively released from necrotic cells. Because of the ability of HMGB1 to sustain chronic inflammation, we investigated whether the protein is present in nasal fluids of patients with different forms of rhinitis.

Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs

Research

Luciana Kase Tanno¹, Moises Calderon², Nikolaos G. Papadopoulos³⁴, Pascal Demoly^5* and on behalf of the EAACI/WAO Task force of a Global Classification of Hypersensitivity/Allergic diseases

Clinical and Translational Allergy 2015, 5:20  doi:10.1186/s13601-015-0063-x

Abstract (provisional)

Background With the aim of actively contributing to the ongoing 11th International Classification of Diseases (ICD) revision, an international collaboration led by the European Academy of Allergy and Clinical Immunology (EAACI) has decided to revise the classification of hypersensitivity/allergic diseases and to validate it for ICD-11 by crowdsourcing the allergist community. However, understanding that the construction of a classification was necessary but not sufficient, we developed a mapping strategy in the attempt to better fit it to the ICD-11 linearization structure.

Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years

Research

Elide Anna Pastorello^1*, Laura Farioli², Laura Michelina Losappio¹, Nuccia Morici³, Matteo Di Biase⁴, Michele Nichelatti⁵, Jan Walter Schroeder¹, Luca Balossi¹ and Silvio Klugmann³

Clinical and Molecular Allergy 2015, 13:14  doi:10.1186/s12948-015-0013-0

Published: 2 June 2015

Abstract

Background

One of the greatest challenges in cardiovascular medicine is to define the best tools for performing an accurate risk stratification for the recurrence of ischemic events in acute coronary syndrome (ACS) patients.

Whistles and wheezes: don't miss diseases

Arch Dis Child Educ Pract Ed 2015;100:132-143 doi:10.1136/archdischild-2013-304604

1. J Cyriac, 
2. K Huxstep

Abstract

Upper airway obstruction (UAO) in infants and children has a broad spectrum of presentations including benign self-resolving conditions, from mild croup, to critical life-threatening conditions which, though uncommon now, require prompt recognition and effective multidisciplinary collaborative management to achieve a good outcome.

Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria

Acta Derm Venereol. 2015 Jun 3. doi: 10.2340/00015555-2150. [Epub ahead of print]

Abajian M1, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, Maurer M, Giménez-Arnau A.

Author information

Abstract

Chronic cold urticaria (ColdU) is a rare disease characterized by mast cell-mediated wheals and angioedema following cold exposure. Second-generation H1-antihistamines, such as rupatadine, are the recommended first-line therapy. As of yet, the effects of rupatadine up-dosing on development of ColdU symptom have only been partially characterized.

Usefulness of open mixed nut challenges to exclude tree nut allergy in children

Brief communication

Francine C. Van Erp^1*, André C. Knulst³, Irene L. Kok², Maartje F. van Velzen¹, Cornelis K. van der Ent¹ and Yolanda Meijer¹

Clinical and Translational Allergy 2015, 5:19  doi:10.1186/s13601-015-0062-y

Published: 16 May 2015

Abstract

Background

To minimize the risk of accidental reactions, atopic children with multiple sensitizations to tree nuts are advised to avoid all nuts. Multiple food challenges would be needed to confirm the clinical relevance, but are too burdensome to be practical.

Successful desensitization in a boy with severe cow´s milk allergy by a combination therapy using omalizumab and rush oral immunotherapy

Case report

Masaya Takahashi, Shoichiro Taniuchi^*, Kazuhiko Soejima, Yasuko Hatano, Sohsaku Yamanouchi and Kazunari Kaneko

Allergy, Asthma & Clinical Immunology 2015, 11:18  doi:10.1186/s13223-015-0084-y

Published: 28 May 2015

Abstract (provisional)

Background Rush oral immunotherapy (OIT) combined with omalizumab (OMB) has been reported to be an effective and safe treatment for severe milk allergies. However, no report has described long-term follow-up observations after OMB discontinuation. The purpose of this case report was to evaluate the safety and efficacy of rush OIT in combination with OMB during a long period of treatment. Case presentation A 5-year-old boy presented with a past history of two severe episodes of anaphylaxis (at the age of 2 and 3 years) after consuming small amounts of cow’s milk (CM).

Real-world research and its importance in respiratory medicine

1. David Price1,2⇑, 
2. Guy Brusselle1,3,4, 
3. Nicolas Roche1,5,6, 
4. Daryl Freeman1,7 and
5. Alison Chisholm1

+Author Affiliations

1. 1Respiratory Effectiveness Group, Cambridge, UK
2. 2University of Aberdeen, Aberdeen, UK
3. 3Department of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium
4. 4Departments of Epidemiology and Respiratory Medicine, Erasmus MC, Rotterdam, The Netherlands
5. 5Respiratory and Intensive Care Medicine, GH Cochin, Site Val de Grace, Paris, France
6. 6Université Paris-Descartes (EA2511), Sorbonne Paris Cité, Paris, France
7. 7East of England Strategic Clinical Network, Norfolk, UK

1. David Price, Academic Centre of Primary Care, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. E-mail: david@rirl.org

Abstract

Educational Aims To improve understanding of:

• The relative benefits and limitations of evidence derived from different study designs and the role that real-life asthma studies can play in addressing limitations in the classical randomised controlled trial (cRCT) evidence base.
• The importance of guideline recommendations being modified to fit the populations studied and the model of care provided in their reference studies.

Data safety and monitoring board in non-industry trials: learning it the hard way

Letter to the Editor

A. Hazenberg^123*, H. A. M. Kerstjens¹³ and P. J. Wijkstra¹²³

Respiratory Research 2015, 16:63  doi:10.1186/s12931-015-0222-6

Letter to the Editor

In the majority of studies, no Data and Safety Monitoring Board (DSMB) is either needed or instituted. We report an investigator initiated study where we should have done this earlier than we did and discuss the lessons we learned.

The EOLUS study was a single center, randomized controlled trial of the initiation of chronic home mechanical ventilation (HMV) at home. Typical indications for HMV are neuromuscular diseases such as amyotrophic lateral sclerosis (ALS) and Duchenne's disease next to thoracic cage deformities. The study was set up to investigate whether the initiation of HMV at home with the help of telemonitoring was not inferior to our usual in hospital start. The primary outcome measure was change in arterial carbon dioxide pressure from baseline to 6 months, for which we calculated a necessary sample size of 52 evaluable patients.